MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.130
-0.040
-3.42%
Closed 16:00 11/26 EST
OPEN
1.150
PREV CLOSE
1.170
HIGH
1.160
LOW
1.100
VOLUME
329.21K
TURNOVER
--
52 WEEK HIGH
2.420
52 WEEK LOW
0.9811
MARKET CAP
99.77M
P/E (TTM)
-5.1178
1D
5D
1M
3M
1Y
5Y
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 11/19 14:04
LPCN: Third Quarter Update
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT
Benzinga · 11/16 14:20
Lipocine Q3 EPS $(0.03) Up From $(0.07) YoY
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.
Benzinga · 11/10 13:22
Lipocine EPS beats by $0.01
Lipocine (NASDAQ:LPCN): Q3 GAAP EPS of -$0.03 beats by $0.01. Revenue of $0.05M Press Release As of September 30, 2021, the Company had $38.7M of unrestricted cash, cash equivalents, and
Seekingalpha · 11/10 13:09
-- Earnings Flash (LPCN) LIPOCINE Reports Q3 Revenue $55,000
MT Newswires · 11/10 08:18
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Benzinga · 11/08 13:24
LPCN: Antares Agreement & NASH Fast Track Change the Calculus
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT TLANDO Licensing Agreement with Antares Pharma On October 18th, Lipocine (NASDAQ:LPCN) announced that it had entered into a licensing agreement with Antares Pharma. The agreement is f...
Zacks Small Cap Research · 11/08 13:18
Lipocine Announces FDA Grants Fast Track Designation To LPCN 1144 For Treatment Of Non-Cirrhotic NASH
Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track
Benzinga · 11/04 13:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LPCN. Analyze the recent business situations of Lipocine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LPCN stock price target is 3.750 with a high estimate of 6.00 and a low estimate of 2.500.
High6.00
Average3.750
Low2.500
Current 1.130
EPS
Actual
Estimate
-0.06-0.05-0.03-0.02
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 57
Institutional Holdings: 9.49M
% Owned: 10.75%
Shares Outstanding: 88.29M
TypeInstitutionsShares
Increased
11
563.04K
New
7
217.18K
Decreased
7
629.54K
Sold Out
2
91.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Financial Officer/Executive Vice President
Morgan Brown
Vice President
Nachiappan Chidambaram
Lead Director/Independent Director
Stephen Hill
Director
John Higuchi
Independent Director
Jeffrey Fink
Independent Director
Richard Ono
No Data
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The Company has a portfolio of product candidates designed to produce pharmacokinetic (PK) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company's lead product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates includes LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which is in Phase II testing and TLANDO XR, an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.